Home > Healthcare & Medical Devices > Contraceptives Market

Contraceptives Market Size By Product (Drugs {Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives}, Devices {Condoms [Male, Female], Diaphragms, Contraceptive Sponges, Vaginal Rings, Subdermal Implants, Intra-uterine Devices (Copper, Hormonal)}), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI430
  • Base Year: 2020
  • Report Format: PDF

Industry Trends

Contraceptives Market size exceeded USD 21.8 billion in 2020 and is anticipated to grow at a CAGR of over 8.2% between 2021 and 2027. The rising awareness pertaining to sexual health is expected to increase the demand and adoption of birth control methods. Similarly, favourable government initiatives and reimbursement scenarios is augmenting the market growth.
 

Contraceptives Market Overview

Get more details on this report - Request Free Sample PDF
 

The upsurge in the use of contraception has reduced the risk of sexually transmitted infections and enhanced health-related outcomes comprising maternal & infant mortality. Moreover, an upsurge in the number of gynecologists preferring these contraception devices for the purpose of birth control is poised to spur the industry growth in the coming years. Rise in awareness of modern contraceptives, increasing use of safe & effective oral pills, and health complications related to teenage pregnancies further stimulate the market expansion.
 

However, the adverse effects of contraceptives drugs are a major concern that may hamper the market progression. The contraceptives oral pills may result in stomach upset, bloating, dizziness, or headache. As per the U.S. National Library of Medicine studies, cigarette smoking surges the risk of severe adverse effects from these medications such as strokes, blood clots, heart attacks, etc. This risk is higher for women age 35 and above.
 

Further, injectable contraceptives have been related to adverse effects including abdominal bloating, weight gain, depression, and alopecia among others. Thus, due to the significant risk linked to the use of contraception drugs, the U.S. FDA regulates the authorization and use of these drugs. The approval requires to submit reasonable assurance regarding the safety and efficacy of the drug. Growing infertility prevalence might hamper the industry expansion during the forecast timeframe.
 

The recent outbreak of COVID-19 has significantly impacted the contraceptives market value. The outbreak inflicted a substantial disease burden along with financial adversities that have impacted the economy. In order to control the spread of the virus, nation-wide lockdowns and emergencies had been declared. Preserving essential health care resources was prioritized in the wake of COVID-19, starting from mid-March 2020, wherein the physicians that prescribe and administer contraceptives were instructed to perform only the essential treatments.
 

However, the advent of novel innovations and technologies during the outbreak become the routine standard of care comprising the use of telemedicine and telehealth in contraception initiation and continuation. Several telehealth modalities enable patients to connect using technology to deliver health care. The implementation of digital health technologies to enhance data for decision-making, evidence-based interventions for consideration in family planning, and reduce contraceptives stockouts has sustained the industry progression. Supporting mobile outreach services to deliver a broad range of contraception products in areas with poor access to healthcare providers has boosted the industry value.
 

Rising prevalence of sexually transmitted diseases (STD) coupled with favourable initiatives to propel the market revenue

Increase in the prevalence of sexually transmitted diseases (STD) across the globe is predicted to promote the market demand. Several research studies have been investigated contraception comprising pills, patches, rings, etc. are very effective in preventing STDs. Further, the WHO is actively operating to enhance and integrate contraceptives services and sexually transmitted infections prevention to reduce the prevalence of these ailments. Several government and non-government organizations are emphasizing on investments to improve awareness and focus on sexual health. In 2019, the Public Health England HIV Prevention Innovation Fund provided around USD 800,000 to support 14 volunteer organizations working to find new approaches to HIV prevention and spread awareness in underserved communities. The UK government has invested around USD 1.6 billion in the global fund to fight AIDS.
 

Growing usage of contraceptive drugs will accelerate the market growth

Contraceptives Market Size

Get more details on this report - Request Free Sample PDF

 

The drugs segment in the contraceptives market was valued at more than USD 5.8 billion in 2020 led by the several advantages delivered by these drugs in controlling the birth rate, preventing pregnancy, and reducing the risk of sexually transmitted infections, etc. As per the WHO report, around 10 million unintended pregnancies among adolescent girls aged 15–19 years occur every year in developing countries. This surging rate of unintended pregnancies is contributing to a rapid increase in demand for contraception drugs to control pregnancies, thereby fostering the industry demand. Oral contraception pills are the most common type of contraception used worldwide. Additionally, recent innovations that lead to the development of a new longer-acting injectable contraception product are driving the industry revenue.
 

High acceptance of technologically advanced products in North America will impel the regional growth

Global Contraceptives Market

Get more details on this report - Request Free Sample PDF

 

U.S. dominated the North America contraceptives market and held 93% of the revenue share in 2020 on account of the favourable government initiatives, the increasing prevalence of sexual transmitted diseases, high rate of unintended pregnancies, etc. The U.S. government has initiated several awareness programs pertaining to contraception and family planning that have s fuelled the revenue of the industry. The unintended pregnancy rate is high in the U.S.
 

Strategic initiatives implemented by major players will support the market expansion

Some of the major companies operating in the market are Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Mayer Laboratories, Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc, Teva Pharmaceuticals Industries Ltd. These leaders are engaged in strategic acquisitions, mergers, collaborations, partnerships, expansions, and product launches among other strategies to maintain a competitive edge. These market participants also focus on research and development activities that enables in garnering maximum market share.
 

Contraceptives market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product, 2016 - 2027 (USD Million)

  • Drugs
    • Oral Contraceptive Pills
    • Injectable Contraceptives
    • Topical Contraceptives  
  • Devices
    • Condoms
      • Male
      • Female
    • Diaphragms
    • Contraceptive Sponges
    • Vaginal Rings
    • Subdermal Implants
    • Intra-uterine Devices
      • Copper
      • Hormonal

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
       
Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The global market size of contraceptives was worth USD 21.8 billion in 2020 and will witness a CAGR of more than 8.2% up to 2027 owing to the surging awareness regarding sexual health and the presence of favorable government initiatives and reimbursement scenarios.

Contraceptives are used to treat numerous menstrual-related symptoms and disorders and can as well as limit pregnancy-related morbidity and mortality, whilst reducing the risks of developing various reproductive cancers.

The drugs segment crossed more than USD 5.8 billion in 2020 will grow with the increasing need to control the birth rate, prevent pregnancy, and reduce the risk of sexually transmitted infections.

The U.S. accounted for over 93% of the revenue share in 2020 and witness significant growth owing to the rising burden of sexually transmitted diseases, higher rate of unintended pregnancies, and the presence of favorable government initiatives.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Published Date: Nov 2021
  • Companies covered: 10
  • Tables & Figures: 268
  • Countries covered: 16
  • Pages: 150

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount